Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
Recruiting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Male/female patients who are at least 18 years of age on the day of informed consent signing. 2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy. 3. Provision of written informed consent for the study. 4. Pregnant women not included 5. Cognitively impaired adults are not included. Exclusion Criteria: None
About the study
To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.
What is being tested
- cell-free DNA (diagnostic test)
Sponsor: M.D. Anderson Cancer Center · Participants: 517 · Started: Feb 23, 2023
Contact the study team
- Chijioke Nze, MD · Phone: 832-729-1752
Official record on ClinicalTrials.gov — NCT05676450
Locations in the U.S.
| Texas | MD Anderson Cancer Center, Houston Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.